Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08EUS
|
|||
| Former ID |
DNCL003476
|
|||
| Drug Name |
CGC-11047
|
|||
| Synonyms |
UNII-2C4Y86R2AX; 2C4Y86R2AX; (Z)-N,N'-bis[3-(ethylamino)propyl]but-2-ene-1,4-diamine; 206991-64-2; CHEMBL3104344; CGC-11047 free base; Pg-11047(free base); AC1O51NW; CHEMBL142464; SCHEMBL2360444; BDBM50445365; 308145-19-9; (Z)-N,N'-Bis[3-(ethylamino)propyl]-2-butene-1,4-diamine; 2-Butene-1,4-diamine, N1,N4-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis(3-(ethylamino)propyl)-, (2Z)-; 2-Butene-1,4-diamine, N,N'-bis[3-(ethylamino)propyl]-, tetrahydrochloride, (2Z)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 2 | [1] | |
| Company |
Progen Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H32N4
|
|||
| Canonical SMILES |
CCNCCCNCC=CCNCCCNCC
|
|||
| InChI |
1S/C14H32N4/c1-3-15-11-7-13-17-9-5-6-10-18-14-8-12-16-4-2/h5-6,15-18H,3-4,7-14H2,1-2H3/b6-5-
|
|||
| InChIKey |
XFWLTFZLLXVKDY-WAYWQWQTSA-N
|
|||
| CAS Number |
CAS 308145-19-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human Deoxyribonucleic acid (hDNA) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00585416) Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Gene expression analysis of HCT116 colon tumor-derived cells treated with the polyamine analog PG-11047. Cancer Genomics Proteomics. 2009 May-Jun;6(3):161-75. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.